Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
NCT03083210Phase 4Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of lanreotide in Neuroendocrine Neoplasm (NEN), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
lanreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03083210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083210.